Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOD1 | P00441 | 1/20 | 0.48 |
| ▸ | POLA1 | P09884 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12887435 | 1.00 | SOD1 (0.48) | SOD1POLA1CYP3A4MAPTMEN1 | |
| SCHEMBL279982 | 0.78 | SOD1 (0.43) | SOD1POLA1CYP3A4MAPTMEN1 | |
| SCHEMBL280353 | 0.78 | SOD1 (0.43) | SOD1POLA1CYP3A4MAPTMEN1 | |
| SCHEMBL267488 | 0.75 | PTGS1 (0.46) | SOD1POLA1CYP3A4MAPTMEN1 | |
| SCHEMBL267401 | 0.75 | PTGS1 (0.46) | SOD1POLA1CYP3A4MAPTMEN1 | |
| SCHEMBL6008134 | 0.75 | PTGS1 (0.46) | SOD1POLA1CYP3A4MAPTMEN1 | |
| SCHEMBL12450207 | 0.75 | PTGS1 (0.46) | SOD1POLA1CYP3A4MAPTMEN1 | |
| SCHEMBL12887758 | 0.75 | PTGS1 (0.46) | SOD1POLA1CYP3A4MAPTMEN1 | |
| SCHEMBL12704709 | 0.74 | SOD1 (0.47) | SOD1POLA1CYP3A4MAPTMEN1 | |
| SCHEMBL12704636 | 0.73 | SOD1 (0.54) | SOD1POLA1CYP3A4MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133915-B2 | Interleukin-1 and tumor necrosis factor-α modulators; syntheses of such modulators and methods of using such modulators | NEREUS PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-7893299-B2 | Acanthoic amide derivatives; inflammation, cancer, cachexia, cardiovascular disease, infections, diabetes, otitis media, sinusitis, transplant rejection | NEREUS PHARMACEUTICALS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20080188475-A1 | Novel Interleukin-1 and Tumor Necrosis Factor-Alpha Modulators, Syntheses of Said Modulators and Their Enantiomers and Methods of Using Said Modulators | NEREUS PHAMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080103328-A1 | Novel Interleukin-1 and Tumor Necrosis Factor-Alpha Modulators, Syntheses of Said Modulators and Their Enantiomers and Methods of Using Said Modulators | NEREUS PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080064753-A1 | Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators | HENSLER, MARY | 2008-03-13 | — | — | US | disclosed |
| US-7342125-B2 | Method of treating inflammation with acanthoic acid derivatives | NEREUS PHARMACEUTICALS, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-7288671-B2 | Interleukin-1 and tumor necrosis factor-α modulators, synthesis of said modulators and their enantiomers and methods of using said modulators | NEREUS PHARMACEUTICALS, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288671-B2 | Interleukin-1 and tumor necrosis factor-α modulators, synthesis of said modulators and their enantiomers and methods of using said modulators | NEREUS PHARMACEUTICALS, INC. (US) | 2007-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103328-A1 | Novel Interleukin-1 and Tumor Necrosis Factor-Alpha Modulators, Syntheses of Said Modulators and Their Enantiomers and Methods of Using Said Modulators | TNF, TNFRSF1A, IL1R1 | SOD1 2575/4885POLA1 2510/4885CYP3A4 2271/4885 |
| US-20080188475-A1 | Novel Interleukin-1 and Tumor Necrosis Factor-Alpha Modulators, Syntheses of Said Modulators and Their Enantiomers and Methods of Using Said Modulators | IL1A, IL1B, TNF | SOD1 3023/4885POLA1 311/4885CYP3A4 1400/4885 |
| US-20080064753-A1 | Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators | IL1A, IL1B, TNF | SOD1 4117/4885POLA1 4404/4885CYP3A4 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.